Weekly chart ramping of an extended base.
Not the cheapest stock in the world, but its a 20% revenue grower, as opposed to all that bloated garbage with zero to single digiet revenue growth that are now sporting north of 30 P/Es. In this world anything with 20+% revenue growth is very hard to find.
Company makes generics along with their own drugs. Business model similar to TEVA.
Multiple new products launches between now and 2015.
Chart looks good to me.
Edited by ogm, 12 August 2013 - 01:36 PM.
